Skip to main content
. 2017 Feb 3;2(1):120–130. doi: 10.1002/btm2.10052

Figure 2.

Figure 2

Coat activity was confirmed by in vitro assays specific for each adjuvant. (a) OVA‐FliC nanoparticles and OVA‐OVA nanoparticles with soluble FliC (sFliC) admixed demonstrated similar levels of TLR‐5‐dependent NFκB activation in Hela cells as compared to OVA‐OVA nanoparticles. Each bar is an average of two technical replicates (n = 2). (b) Complement activation as determined by anti‐TCC ELISA after mixing nanoparticles with human serum. IgM‐coated OVA nanoparticles and uncoated OVA nanoparticles demonstrated similar levels of complement activation. Each average is composed of two technical replicates in each of two serum samples (n = 4)